Aortic Stenosis

Chapter: Aortic Stenosis
McMaster Section Editor(s): P.J. Devereaux
Section Editor(s) in Interna Szczeklika: Andrzej Budaj, Wiktoria Leśniak
McMaster Author(s): Matt Sibbald, Tej Sheth, Hisham Dokainish
Author(s) in Interna Szczeklika: Marek Konka, Piotr Hoffman
Additional Information

Definition, Etiology, PathogenesisTop

Aortic stenosis (AS) results from thickened or calcified valve leaflets leading to restricted leaflet motion, reduced aortic valve area (AVA), and transvalvular flow obstruction. AS is most frequently an acquired disease (age-related degenerative valve disease, with rheumatic disease rarely seen), but may also be congenital (most frequently a bicuspid aortic valve).

Clinical Features and Natural HistoryTop

1. Symptoms: AS remains asymptomatic for a long time; it may cause angina, palpitations, dizziness, presyncope or syncope, dyspnea, and in more advanced disease, resting dyspnea. Classification of severity: Table 3.17-3.

2. Signs: Cardiac impulse is diffuse, sustained, and displaced laterally and inferiorly. A systolic thrill may be palpable at the base of the heart and transmitted to the carotid arteries (in patients with severe stenosis). An ejection systolic murmur is present, although its intensity may not reflect the severity of stenosis; the murmur radiates to the carotid arteries and the later the murmur peaks, the more severe the stenosis. An aortic ejection click is audible in patients with elastic leaflets (commonly bicuspid valves). The aortic component of the second heart sound is soft, reverse split, or absent (in severe stenosis); sometimes a fourth heart sound is audible. The pulse is low-amplitude and slow-rising—“parvus and tardus” (in elderly patients these pulse features may be absent due to systemic arteriosclerosis). Patients may have a brachial-radial delay.

3. Natural history: The rate of progression of AS is highly variable. In asymptomatic patients, the risk of sudden cardiac death is low, but rapidly increases with the onset of the 3 cardinal symptoms: syncope, angina, and heart failure. The average survival of untreated patients with such symptoms is 2 to 3 years.


Diagnosis is based on typical clinical features and echocardiography results.

Diagnostic Tests

1. Electrocardiography (ECG) is usually normal in mild to moderate AS. In severe AS, features of left ventricular (LV) hypertrophy with strain pattern are commonly present.

2. Chest radiography remains normal for many years. In severe AS, LV hypertrophy and poststenotic dilation of the ascending aorta are observed. Calcifications of the aortic valve may be seen.

3. Doppler echocardiography is used to confirm the diagnosis of AS, assess its severity, evaluate LV structure and function, assess the aortic root and ascending aorta, and monitor the course of the disease. A thickened, calcified aortic valve with reduced leaflet excursion is seen. Doppler echocardiography allows for determination of the severity of stenosis by measuring the aortic jet velocity, peak and mean transvalvular pressure gradients, and AVA (Table 3.17-3). In patients with low-flow, low-gradient AS (AVA <1 cm2, but a mean aortic valve gradient <40 mm Hg and/or peak aortic valve velocity <4.0 cm/s), the most common cause is depressed left ventricular ejection fraction (LVEF) (ejection fraction <40%) resulting in low transvalvular flow; in such cases, dobutamine stress echocardiography can be performed to distinguish true severe AS from “pseudosevere AS” and to help predict perioperative mortality (expert input usually required).Evidence 1Moderate Quality of Evidence (moderate confidence that we know the true prognostic value of the test). Quality of Evidence lowered due to imprecision (low number of observed events). Monin JL, Quéré JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation. 2003 Jul 22;108(3):319-24. Epub 2003 Jun 30. PubMed PMID: 12835219. Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am Coll Cardiol. 2008 Apr 15;51(15):1466-72. doi: 10.1016/j.jacc.2007.10.067. PubMed PMID: 18402902. 

4. Cardiac catheterization may be considered in cases of inconsistent clinical and echocardiographic findings, and to exclude significant coronary artery stenosis before aortic valve surgery. Coronary angiography is recommended before surgical treatment of AS in patients with severe valvular heart disease and one of the following:

1) A history of coronary artery disease (CAD).

2) Suspected myocardial ischemia (chest pain, abnormal results of noninvasive investigations).

3) LV systolic dysfunction.

4) Men >40 years of age, postmenopausal women.

4) ≥1 cardiovascular risk factor (in patients at low risk of atherosclerosis, the diagnosis of CAD may be excluded using multislice computed tomography [MSCT] coronary angiography).

Differential Diagnosis

Differential diagnosis should include supravalvular AS and membranous subvalvular stenosis, both of which can be readily identified by echocardiography. Dynamic LV outflow tract obstruction can cause flow acceleration and high transvalvular gradients; however, the carotid upstroke is rapid (not delayed as in AS), while on echocardiography, the aortic valve is not restricted in motion and the shape of the Doppler spectral tracing is “dagger-shaped,” not parabolic as in AS.

Treatment Top

General Considerations

1. Mild or moderate AS: Medical treatment and follow-up visits (every 1-2 years in mild AS and every year in moderate AS) with echocardiography (every 3-5 years in mild AS and every 1-2 years in moderate AS).

2. Severe AS: In general, surgical opinion should be obtained; further details: below.

Invasive Treatment

1. Aortic valve replacement (AVR) surgery is the key method of treatment in the case of severe AS. Fifty percent of patients with severe AS have coexisting significant CAD. In such cases, coronary artery bypass grafting (CABG) is performed concomitantly with AVR. AVR is recommended in:

1) Patients with severe AS and symptoms related to AS (syncope, angina, or heart failure); in such cases, urgent surgery is indicated.

2) Asymptomatic patients with severe AS in any of the following cases:

a) LVEF <50% due to AS.

b) Abnormal exercise test results showing symptoms on exercise clearly related to AS (surgery may be considered if exercise leads to a drop in blood pressure below baseline).

c) Admission for CABG, surgery of the ascending aorta, or nonaortic valve surgery (surgery may be also considered in patients with moderate AS).

Patients with implanted prosthetic mechanical valves require lifelong oral anticoagulant therapy (with the international normalized ratio dependent on thrombogenicity of the artificial valve: Table 3.17-5). In patients considered to have acceptable risk of bleeding, especially those with coexisting CAD, low-dose aspirin could be added.Evidence 2Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). Moderate Quality of Evidence (moderate confidence that we know true effects of intervention). Quality of Evidence lowered due to the risk of bias and imprecision. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e576S-600S. doi: 10.1378/chest.11-2305. PubMed PMID: 22315272; PubMed Central PMCID: PMC3278057. In the case of relative contraindications to oral anticoagulants (eg, athletes or women planning to become pregnant), consider other modalities of surgical treatment: valvuloplasty, implantation of a heterograft (bioprosthetic valve) or a homograft, the Ross procedure (using the patient’s own pulmonary valve to replace the diseased aortic valve, with implantation of a homograft to replace the pulmonary valve).

2. Transcatheter aortic valve implantation (TAVI), a percutaneous method of aortic valve replacement, is an alternative to surgery for patients with severe symptomatic AS who are likely to have their quality of life and, in the case of inoperable patients, also mortality risk improved by TAVI. In patients with severe AS who are ineligible for surgery, TAVI may be considered,Evidence 3Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). Moderate Quality of Evidence (moderate confidence that we know true effects of intervention). Quality of Evidence lowered due to the large number of patients who crossed over and a relatively small number of events. Kapadia SR, Leon MB, Makkar RR, et al; PARTNER trial investigators. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Jun 20;385(9986):2485-91. doi: 10.1016/S0140-6736(15)60290-2. Epub 2015 Mar 15. PubMed PMID: 25788231. and in those who have high surgical risk, TAVI is an acceptable (and may be the preferable) option.Evidence 4Weak recommendation (benefits likely outweigh downsides, but the balance is close or uncertain; an alternative course of action may be better for some patients). Moderate Quality of Evidence (moderate confidence that we know true effects of intervention). Quality of Evidence lowered due to the degree of imprecision. Mack MJ, Leon MB, Smith CR, et al; PARTNER 1 trial investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015 Jun 20;385(9986):2477-84. doi: 10.1016/S0140-6736(15)60308-7. Epub 2015 Mar 15. PubMed PMID: 25788234. With advancements in percutaneous valve technology and evolution of the technique, TAVI may become a preferred method of AS treatment in the future.

Absolute contraindications to TAVI:

1) Absence of a “heart team” and no cardiac surgery on site.

2) Appropriateness of TAVI, as an alternative to AVR, not confirmed by a “heart team.”

3) Estimated life expectancy <1 year.

4) Improvement in the quality of life by TAVI is unlikely due to comorbidities.

5) A severe primary associated disease of other valves with a major contribution to the patient’s symptoms that can be treated only by surgery.

6) Inadequate annulus size (<18 mm, >29 mm).

7) A thrombus in the left ventricle.

8) Active endocarditis.

9) Elevated risk of coronary ostium obstruction (asymmetric valve calcification, a short distance between annulus and coronary ostium, small aortic sinuses).

10) Plaques with mobile thrombi in the ascending aorta or arch (such patients could be considered for [higher risk] transapical TAVI).

11) For the transfemoral or subclavian approach: Inadequate vascular access (vessel size, calcification, tortuosity); in such cases, transapical TAVI can be considered.

Relative contraindications:

1) Bicuspid or noncalcified valves.

2) Untreated CAD requiring surgical revascularization; selected patients with CAD can be treated with coronary stenting and TAVI.

3) Hemodynamic instability.

4) LVEF <20%.

5) For the transapical approach: Severe pulmonary disease, LV apex not accessible.

Adverse effects: Vascular complications (including hemorrhage), stroke, paravalvular leak, AV block.

3. Percutaneous aortic balloon valvuloplasty (PABV): In adults, restenosis usually occurs within 6 to 12 months, and aortic insufficiency after PABV is a significant concern. This method should only be considered:

1) As a “bridging” procedure before AVR in hemodynamically unstable patients in whom immediate surgery may be associated with high risk of complications.

2) As a palliative procedure in patients with severe comorbidities.

3) As a procedure allowing for an urgent noncardiac surgery.

Medical Treatment

1. To reduce or control symptoms:

1) Hypertension: Control hypertension with beta-blockers or angiotensin-converting enzyme inhibitors (ACEIs) (care should be taken to avoid overmedication and resultant hypotension). With ACEIs, start with a low dose and slowly titrate. In patients who have symptomatic AS, try to avoid preload- and afterload-reducing agents that may produce hypotension.

2) Pulmonary congestion: Diuretics and ACEIs (use with caution, as a too rapid preload reduction decreases cardiac output and blood pressure), beta-blockers (in patients with LV hypertrophy and LV systolic dysfunction, or with atrial fibrillation).

3) Atrial fibrillation: Electrical cardioversion (not to be performed prior to surgical treatment of AS in patients with severe AS who are hemodynamically stable). In the case of persistent atrial fibrillation, administer beta-blockers (the preferred agents) or calcium channel blockers (diltiazem or verapamil) to control the ventricular rate, although such calcium channel blockers are contraindicated in patients with depressed LVEF (<50%). Digoxin can be added to beta-blockers or calcium channel blockers to augment ventricular rate control. Amiodarone can be used in selected cases alone or with beta-blockers or calcium channel blockers, but it should be avoided if the patient is receiving digoxin.

4) Angina: Beta-blockers, nitrates (use with caution).

2. Prevention of infective endocarditis: see Infective Endocarditis.

Complications Top

Sudden cardiac death, peripheral embolism, infective endocarditis (more frequent in younger patients with minor valvular lesions), coagulopathy (acquired von Willebrand syndrome), aortic dissection (most often in patients with a bicuspid aortic valve and aortopathy), right ventricular failure (rare).

Prognosis Top

The prognosis is favorable in asymptomatic patients. The onset of symptoms is associated with a worse prognosis, as the average survival time is 2 years from the onset of heart failure, 3 years from the onset of syncope, and 5 years from the onset of angina. Surgical treatment improves the prognosis.


Table 3.17-3. Classification of aortic stenosis

Aortic stenosis




AVA (cm2)



<1.0 (0.6 cm2/m2 BSA)

Mean gradient (mm Hg)




Jet velocity (m/s)




Based on Circulation. 2014;129(23):e521-643.

AVA, aortic valve area; BSA, body surface area.

Table 3.17-5. Antithrombotic treatment in patients with mechanical prosthetic valves

Risk of thrombosis associated with the prosthesis

Examples of mechanical valves

Target international normalized ratio depending on the number of risk factorsa




– Carbomedics (aortic)

– Medtronic Hall

– St. Jude Medical

– On-X




Other bileaflet valves




– Lillehei-Kaster

– Omniscience

– Starr-Edwards

– Björk-Shiley

– Other tilting disc valves



a Risk factors: replacement of the mitral or tricuspid valve; prior thromboembolic event, atrial fibrillation, mitral stenosis of any severity, left ventricular ejection fraction <35%.

Adapted from Eur Heart J. 2012;33(19):2451-96.

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.